Literature DB >> 11884557

Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys.

Lewis Markoff1, Xiaou Pang, Huo-shu Houng Hs, Barry Falgout, Raymond Olsen, Estella Jones, Stephanie Polo.   

Abstract

We recently described the derivation of a dengue serotype 2 virus (DEN2mutF) that exhibited a host range-restricted phenotype; it was severely impaired for replication in cultured mosquito cells (C6/36 cells). DEN2mutF virus had selected mutations in genomic sequences predicted to form a 3' stem-loop structure (3'-SL) that is conserved among all flavivirus species. The 3'-SL constitutes the downstream terminal similar95 nucleotides of the 3' noncoding region in flavivirus RNA. Here we report the introduction of these same mutational changes into the analogous region of an infectious DNA derived from the genome of a human-virulent dengue serotype 1 virus (DEN1), strain Western Pacific (DEN1WP). The resulting DEN1 mutant (DEN1mutF) exhibited a host range-restricted phenotype similar to that of DEN2mutF virus. DEN1mutF virus was attenuated in a monkey model for dengue infection in which viremia is taken as a correlate of human virulence. In spite of the markedly reduced levels of viremia that it induced in monkeys compared to DEN1WP, DEN1mutF was highly immunogenic. In addition, DEN1mutF-immunized monkeys retained high levels of neutralizing antibodies in serum and were protected from challenge with high doses of the DEN1WP parent for as long as 17 months after the single immunizing dose. Phenotypic revertants of DEN1mutF and DEN2mutF were each detected after a total of 24 days in C6/36 cell cultures. Complete nucleotide sequence analysis of DEN1mutF RNA and that of a revertant virus, DEN1mutFRev, revealed that (i) the DEN1mutF genome contained no additional mutations upstream from the 3'-SL compared to the DEN1WP parent genome and (ii) the DEN1mutFRev genome contained de novo mutations, consistent with our previous hypothesis that the defect in DEN2mutF replication in C6/36 cells was at the level of RNA replication. A strategy for the development of a tetravalent dengue vaccine is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884557      PMCID: PMC136019          DOI: 10.1128/jvi.76.7.3318-3328.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Detection of stable secondary structure at the 3' terminus of dengue virus type 2 RNA.

Authors:  P M Mohan; R Padmanabhan
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

2.  HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA.

Authors:  D P Bartel; M L Zapp; M R Green; J W Szostak
Journal:  Cell       Date:  1991-11-01       Impact factor: 41.582

3.  RNA recognition by Tat-derived peptides: interaction in the major groove?

Authors:  K M Weeks; D M Crothers
Journal:  Cell       Date:  1991-08-09       Impact factor: 41.582

Review 4.  Flavivirus genome organization, expression, and replication.

Authors:  T J Chambers; C S Hahn; R Galler; C M Rice
Journal:  Annu Rev Microbiol       Date:  1990       Impact factor: 15.500

5.  Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain).

Authors:  K Irie; P M Mohan; Y Sasaguri; R Putnak; R Padmanabhan
Journal:  Gene       Date:  1989-02-20       Impact factor: 3.688

6.  Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity.

Authors:  B H Tan; J Fu; R J Sugrue; E H Yap; Y C Chan; Y H Tan
Journal:  Virology       Date:  1996-02-15       Impact factor: 3.616

7.  A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.

Authors:  R Edelman; C O Tacket; S S Wasserman; D W Vaughn; K H Eckels; D R Dubois; P L Summers; C H Hoke
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

8.  Stable secondary structures at the 3'-end of the genome of yellow fever virus (17 D vaccine strain).

Authors:  T Grange; M Bouloy; M Girard
Journal:  FEBS Lett       Date:  1985-08-19       Impact factor: 4.124

9.  Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus.

Authors:  E V Koonin
Journal:  J Gen Virol       Date:  1993-04       Impact factor: 3.891

10.  BHK cell proteins that bind to the 3' stem-loop structure of the West Nile virus genome RNA.

Authors:  J L Blackwell; M A Brinton
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  17 in total

Review 1.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2.

Authors:  Smita Jaiswal; Navin Khanna; S Swaminathan
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Potential of ancestral sylvatic dengue-2 viruses to re-emerge.

Authors:  Nikos Vasilakis; Elisabeth J Shell; Eric B Fokam; Peter W Mason; Kathryn A Hanley; D Mark Estes; Scott C Weaver
Journal:  Virology       Date:  2006-10-02       Impact factor: 3.616

Review 4.  Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis.

Authors:  Benjamin M Althouse; Anna P Durbin; Kathryn A Hanley; Scott B Halstead; Scott C Weaver; Derek A T Cummings
Journal:  Virology       Date:  2014-02-14       Impact factor: 3.616

5.  Size heterogeneity in the 3' noncoding region of South American isolates of yellow fever virus.

Authors:  Juliet E Bryant; Pedro F C Vasconcelos; Rene C A Rijnbrand; J P Mutebi; Stephen Higgs; Alan D T Barrett
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Highly efficient production of a dengue pseudoinfectious virus.

Authors:  Xiaowu Pang; Yinhan Guo; Yanfei Zhou; Wenchuan Fu; Xinbin Gu
Journal:  Vaccine       Date:  2014-05-05       Impact factor: 3.641

Review 7.  Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus.

Authors:  Kathryn A Hanley; Thomas P Monath; Scott C Weaver; Shannan L Rossi; Rebecca L Richman; Nikos Vasilakis
Journal:  Infect Genet Evol       Date:  2013-03-20       Impact factor: 3.342

8.  A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.

Authors:  Xiao-Feng Li; Yong-Qiang Deng; Hui-Qiang Yang; Hui Zhao; Tao Jiang; Xue-Dong Yu; Shi-Hua Li; Qing Ye; Shun-Ya Zhu; Hong-Jiang Wang; Yu Zhang; Jie Ma; Yong-Xin Yu; Zhong-Yu Liu; Yu-Hua Li; E-De Qin; Pei-Yong Shi; Cheng-Feng Qin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

9.  Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.

Authors:  Joseph E Blaney; Neeraj S Sathe; Laura Goddard; Christopher T Hanson; Tammy A Romero; Kathryn A Hanley; Brian R Murphy; Stephen S Whitehead
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

10.  A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys.

Authors:  Stephen S Whitehead; Barry Falgout; Kathryn A Hanley; Joseph E Blaney; Lewis Markoff; Brian R Murphy
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.